Commentary: Meta-analysis of trials comparing antidepressants with active placebos
- 1 March 1998
- journal article
- review article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 172 (3), 232-234
- https://doi.org/10.1192/s0007125000260352
Abstract
This attempt to establish treatment effect sizes follows a tradition, which dates back over 20 years, of assessing the effects of antidepressant treatment under ‘blinder conditions'. The method adopted by Moncrieff et al has some merit but involves a recourse to studies, many of which are over 30 years old. While the studies may not be seriously flawed, it is difficult to have much confidence in them. None appears to have included what the authors describe as an ‘inert’ placebo, which strictly speaking would be a non-drug arm to the study. The number of studies is small. The dose of drugs used, which might be expected to have some influence on outcomes, is not mentioned. Finally, as experience with studies in obsessive-compulsive disorder indicates, treatment effect sizes can vary substantially from one decade to another –most probably because different individuals are recruited although all may apparently meet the same diagnostic criteria.Keywords
This publication has 4 references indexed in Scilit:
- MirtazapineThe Journal of Clinical Psychiatry, 1998
- Meta-analysis of trials comparing antidepressants with active placebosThe British Journal of Psychiatry, 1998
- Child and learning disability psychopharmacologyJournal of Psychopharmacology, 1997
- A meta-analysis of antidepressant outcome under "blinder" conditions.Journal of Consulting and Clinical Psychology, 1992